Abstracts describing work posted to a preprint server prior to submission to ASH will be considered, but preprint posting must be disclosed and a link to the preprint provided. During submission, authors of late-breaking abstracts will be asked to explain why their abstract was not ready by the regular deadline (August 2) and deserves to be considered as late-breaking. ), In the event the abstract is NOT selected for oral or poster presentation, all submitting authors must decide whether they want their abstract to be published in the online-only issue of. All authors and co-authors are required to provide any information concerning personal or professional circumstances and financial relationships with ineligible companies that might reasonably be expected to affect the authors view on the presentation. Outstanding Abstract Achievement Award winners receive a $500 honorarium plus annual meeting travel reimbursement (coach airfare and two nights' hotel accommodations). from my presentation materials. To assess the effects of LRF loss on the mouse erythroid transcriptome, we performed RNA-Seq analysis using splenic erythroblasts from control and LRF conditional knockout (Zbtb7aF/F Mx1-Cre+) mice. Equity holder in privately-held company (including stock options, but excluding indirect investments through mutual funds and the like) in a publicly traded company, Research or clinical trial funding or other support (including grants received by your institution), Honoraria directly received from an entity, Membership on an entitys board of directors, speakers bureau, or its advisory committees, Any other financial relationship with an ineligible company company. The content I am responsible for will only use generic names of products, or if trade names appear, is the use of those trade names will be justified (e.g., product is known more widely for the trade name or the product does not have a generic name). 6Cell Engineering Division, RIKEN BioResource Center, Tsukuba, Japan ASH members are urged to use their best judgment in restricting sponsorship to a reasonable number of abstracts, keeping in mind that they are endorsing the authenticity and quality of each abstract that they sponsor. There is a $85 nonrefundable handling fee for submitting an abstract. The abstract may be structured (i.e., abstracts divided into sections using terms such as Introduction, Methods, Results, Conclusions, etc.) ASH reserves the right to replace proprietary names with generic names to adhere to this policy. If your abstract is accepted, the e-mail will specify whether it is accepted as plenary, oral, or poster presentation or will be published online only, without a presentation. Work already posted to a preprint server will not be considered for the Late-Breaking Abstracts session. The program will automatically place an asterisk (*) after the name of each non-member author. Late-breaking abstracts will undergo regular peer-review evaluation.
Use the information for trading in the securities of any issuer or provide it to others who may use it for securities-trading purposes. Send related correspondence and questions regarding abstract submissions or notifications to: ASHabstracts@hematology.org. Failure to submit presentation by November 16th will result in removal of presenting privileges, to be noted by Presentation Not Available in meeting materials. If you have not received an e-mail notification by October 5, 2022, contact, To ensure that you can receive e-mail correspondence from ASH, please. By completing this section of the online abstract submission, you agree that you have read the. The presentation at the annual meeting must reflect the submitted abstract. Abstracts submitted to ASH are embargoed from the time of submission.
Special Greek and mathematical symbols are available in a character map within the submission system. This annual award in partnership with International Paroxysmal Nocturnal Hemoglobinuria (PNH) Interest Group (IPIG) shall be granted to up to two trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious PNH focused abstracts submitted in the fields of Red Cells and Erythropoiesis or Bone Marrow Failure. These choices must be made at the time of submission and cannot be changed after the review committee has reached its decision. The author(s) are aware that the withdrawal deadline for ASH Annual Meeting abstracts is September 16, 2022, and understand that abstracts cannot be withdrawn after September 16.. To register, you must complete and return an Attendee Registration Form, or. If that is not the case, the authors should choose poster as their preference. The content I am responsible for will be free of logos or other corporate identifiers of healthcare industry companies, specifically those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. If none of the abstract authors is an ASH member, the program will ask you to provide the name of the ASH member who is sponsoring the abstract. Our findings reveal a novel molecular mechanism regulating -globin silencing and may open a new window for therapeutic targeting in the treatment of hemoglobinopathies. Upon abstract acceptance for presentation at the annual meeting, the contents and conclusions of the abstract are embargoed from publication.
During submission, submitters must choose the formats in which they would be willing to present/publish their abstract. During online submission, you must indicate whether you prefer to have your abstract withdrawn if it is not accepted as an oral or poster presentations at the ASH annual meeting. (Note the exception for abstracts submitted to other ASH meetings in the Eligibility section above.) The presenting author must be one of the co-authors listed on the submitted abstract. This means that the data in the abstract cannot be published in a journal once submitted for the ASH annual meeting until the meeting is concluded.
Dr. Bigi served as associate professor of Clinical Immunology at the University of Milan from 1985 until his death in 2002 and was one of the first researchers to predict the presence of stem cells in the peripheral blood. 5MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Oxford University, Oxford, United Kingdom All research and studies reported in submitted abstracts that involve human and animal subjects must comply with the guiding principles for experimentalprocedures, Data from the long-term follow-up of previously presented or published clinical trials may be submitted only if significant new information can be shown. The list of award recipients will also be posted on the ASH website by November.
In the event that an abstract is not chosen for oral presentation, it can still be chosen for poster presentation. 4School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, Australia Netscape Navigator 7.7+ is supported, but its use is discouraged, since not all features are available. The64th Annual Meeting of the American Society of Hematology (ASH) will be held Saturday, December 10, through Tuesday, December 13, 2022, in New Orleans, Louisiana. We realize decisions about attendance may not be feasible before the abstract submission deadline, and we will accommodate necessary changes as needed. Please note that submitting an abstract does not register you for the ASH annual meeting. This annual award in partnership with the Japanese Society of Hematology (JSH) shall be granted to up to three trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are. Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by ASH.
Notably, the HbF reactivation occurred without changes in levels of transcripts encoding known HbF repressors, including BCL11A, the principal known switching factor. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committee or review panels, board memberships, and other activities from which remuneration is received, or expected. Authors assign copyright of the abstract to ASH upon submission, unless one of the authors is a U.S. Federal employee (in such case, ASH does not hold copyright). Funnell, PhD4, Chris Fisher, PhD5, Maria Suciu5, Gabriella E. Martyn4, Laura J. Norton4, Ruijia Zhu1, Ryo Kurita, PhD6, Yukio Nakamura, MD, PhD6, Jian Xu, PhD7, Douglas R. Higgs, FRS5, Merlin Crossley, DPhil4, Daniel E. Bauer, MD, PhD3, Stuart H. Orkin, M.D.8, Peter V. Kharchenko, PhD2 and Takahiro Maeda, MD, PhD1 Research funding from ineligible companies should be disclosed by the principal or named investigator even if that individuals institution receives the research grant and manages the funds. If the first author is unable to attend in person, another abstract author able to attend in person may be substituted as the presenter. Purchase orders and checks will not be accepted.
To apply, applicants must first submit an abstract as a trainee to the ASH annual meeting through the online abstract submission system by August 2, 2022. If no financial relationships with ineligible companies exist, this must be stated as well.
Supporting a direct role of LRF at the -globin cluster, we observed several significant enrichment of LRF-ChIP binding signals at adult (HBB), fetal (HBG1) globin loci and the upstream hypersensitivity (HS) sites within the locus control region (LCR). Data from peer-reviewed content is publicly available via major search engines (such as PubMed, Google Scholar, etc.). If an author has more than one abstract accepted, each presentation will be materially confined to the information in the abstract selected for the specific session; The presenting author will be available to present the abstract if selected for the program. HbF levels in LRF KD cells (49-70%) were much greater than those seen in parental or scrambled-shRNA transduced cells. Any references should be noted as citations within the text and not as footnotes at the end of the abstract. Each awardee shall receive a $2,000 grant and complimentary registration to the current years ASH annual meeting.
Minority Graduate Student Abstract Achievement Award applicants will be notified as to whether or not they received an award by late October. Strikingly, HUDEP-2 lines lacking both LRF and BCL11A exhibited almost a complete switch in expression from adult- to fetal-type globin, suggesting that these two factors cumulatively represent the near entirety of -globin repressive activity in adult erythroid cells. More information on requesting such an exception can be found on the. Once the abstract is submitted to ASH, no further changes can be made to the preprint, including the abstract, nor may the preprint be updated if the abstract is accepted for presentation at ASH. If I have been trained or utilized by an ineligible company (commercial interest) or its agent as a speaker (e.g. Electronic submission works optimally with Microsoft Internet Explorer 7+, Mozilla Firefox 3.0+, and Safari or MAC OS 10.4+. Abstracts should be written in clear and concise English, so that reviewers are able to focus solely on the scientific merits of the submission. In addition, this platform will help increase the visibility of ongoing clinical trials; and ultimately facilitate patient recruitment.
Be sure to select from the review category that best describes your abstract. Non-proprietary (generic/scientific) names should be used and should be lowercase. Each abstract author agrees and certifies that they: have read all the rules and agrees to be bound by them, are responsible for submission of the abstract in accordance with the rules, and. There will be no exceptions. Your letter must be typed on your institutions letterhead, signed by the senior investigator, saved in PDF format, and uploaded to the online abstract submission system. ASH requires that abstract presenters of oral or poster presentations attend the meeting and present their abstract and respond to questions in person. 8Department of Pediatric Hematology-Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Conflict-of-Interest Disclosure Policy, Author Responsibility Regarding Financial Relationship Disclosure. In particular, the abstract title, authorship, and scientific content of the presentation at the annual meeting must match the submitted abstract, although updates on results may be added. This annual award in partnership with the Haematology Society of Australia and New Zealand (HSANZ) shall be granted to up to two trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are. If after the September 16 withdrawal deadline, the presenting author of a poster is unable to attend the meeting in person and a co-author cannot be identified to replace the presenter, the author should submit a request to, All abstracts accepted for presentation (plenary, oral, or poster) at the ASH annual meeting are published in a special online-only issue of, Previously published abstracts will not be published in, Abstracts not selected for presentation will also be published online-only on the. Non-members will be able to find all relevant annual meeting information on the ASH website and can access the online registration and hotel reservation program beginning August 10, 2022. Use standard abbreviations. Authors must retain copyright of the abstract so that it may be transferred to the American Society of Hematology if the abstract is accepted, per ASHs copyright policy. Poster presentations will consist of 3-5 minute recordings accompanying a slide deck on the virtual platform. Submissions that are incomplete by the deadline will be rejected. TiPs abstracts are expected to provide investigators with opportunities to discuss planned and ongoing clinical trials; enabling translational researchers, clinical and industry investigators, statisticians, and regulators to become informed about these clinical trials and to allow for early engagement and collaboration, as appropriate. Abstracts noted with a preference for poster presentation will NOT be considered for oral presentation, regardless of score. Any recommendations for patient care must be based on current science, evidence, and clinical reasoning, while giving a fair and balanced view of diagnostic and therapeutic options. Abstracts may not be withdrawn after September 16. The recipient receives a $5,000 grant and a $1,000 allowance for travel and expenses to the ASH annual meeting. Authors select whether they prefer oral or poster presentation. Takeshi Masuda, PhD1, Xin Wang, PhD2, Manami Maeda, M.D., PhD1, Matthew C. Canver, B.S.3, Falak Sher, PhD3, Alister P.W.
For ASH members, Early-Bird Registration will be available July 20, 2022. The site opens on Thursday, June 2, and the abstract submission deadline is Tuesday, August 2, 2022, 11:59 p.m. Pacific time. Obtaining copyright transfer consent from co-authors. An abstract must include primary scientific, clinical, meta-analytic or epidemiologic data. Abstracts describing innovative Trials in Progress (TiP) [i.e., trials that have not reached the primary endpoint] are now eligible for submission and consideration for the ASH annual meeting program. Abstract Achievement Award recipients will be notified if they will receive an award by late October 2022. For the research to be eligible for presentation at the ASH annual meeting, information contained in the abstract, as well as additional data and information to be presented about the research at the annual meeting, may not be made public before the abstract has been published/presented at the ASH annual meeting. Non-text content (. Also, lowercase to when used as an infinitive. speakers bureau) for any commercial interest, the promotional aspects of that presentation will not be included in any way with this activity or publication. Read the Embargo Policy section of the Call for Abstracts for more information. Do not put a period at the end of the title. Your name, degree, institutional affiliation, address, phone number, and e-mail address must be provided. 1Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA Abstract Achievement Award recipients will be notified by email if they will receive an award by late October.
The corresponding author should be the first author (presenter) of the abstract, unless otherwise noted during submission. This annual award is given to an Italian trainee (undergraduate, medical, or graduate student, resident physician, or post-doctoral fellow) based at an Italian institution who is. If necessary, you may include a proprietary name in parentheses directly following the generic name after its first mention in the body of the abstract; the first letter of the name of a proprietary drug should be capitalized. Payment must be made by credit card; Visa, MasterCard, and American Express are accepted. The first author listed for each abstract serves as the presenting author and as the primary contact for all correspondence regarding the abstract, unless otherwise specified under the Contact Information section of the online abstract submission system. To submit an abstract, the following criteria must be met: In contrast to past years, oral abstract and poster presentations will no longer be contained in the ACCME-accredited portion of the annual meeting. We next performed chromatin-immunoprecipitation and sequencing (ChIP-Seq) with an anti-LRF antibody using HSPC-derived proerythroblasts and HUDEP-2 cells. Pre-recorded presentations for both oral and poster presentations are required by November 16th. In addition to the regular eligibility criteria listed above, TiP abstracts must fulfill the following criteria: Recognizing that the results of some top-quality research may not be available by the general abstract submission deadline, the ASH Program Committee offers an option for late-breaking abstracts. The author must provide an explanation (see section below) to show how the abstract contains significant new information. This means that the identical abstract may not be republished or submitted to another meeting. Data are accepted for journal publication before the abstract submission closing date. For such abstracts, copyright remains with the current holder. This annual award is made possible by a grant from the Giuseppe Bigi Association, named for the late Giuseppe Bigi, MD, a well-known Italian scientist. How to be considered for an Abstract Achievement Award: All trainee authors must upload the required letter into the program in order to complete the abstract submission. or unstructured. LRF loss also reactivated human fetal globin expression in vivo in LRF conditional KO mice harboring the human -globin gene cluster as a yeast artificial chromosome transgene (-YAC).
Publication before the meeting may result in the abstract being removed from the meeting.
Pay careful attention to superscripts, type case font sizes, and special characters when copy/pasting abstract text. During this time, ASH members can access the online meeting registration and hotel reservation program before it is open to the general public. If the Embargo Policy is violated, the abstract may be withdrawn by ASH from presentation at the annual meeting and from publication. Registration will open July 20, 2022, for ASH members and August 10, 2022, for non-members.
LRF-deficient adult erythroblasts showed significant induction of Hbb-bh1, but not Hbb-y. Abstracts cannot be submitted and will not be reviewed without proper payment and completion of the Submission Information and Disclosure sections of the online abstract submission program. This annual award in partnership with the Society Italiana di Ematologia (SIE) shall be granted to up to two trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are.
(Please note that declining to have your abstract considered for poster presentation does not improve its chances of being accepted as an oral presentation. An exception may be granted in cases in which the Securities and Exchange Commission (SEC) requires a press release to comply with security laws. ASH abides by rules formulated by the ACCME that require that you disclose any financial relationship you or your spouse/partner have had within the past 24 months with an ineligible company (formerly commercial interest) as defined by the ACCME: Ineligible companies are those whose primary business is producing, marketing, re-selling, or distributing healthcare products used by or on patients. ZBTB7A/ cells exhibited HbF levels greater than 60%, while that of parental cells was less than 3%. During the disclosure submission process, you will also be required to indicate your compliance with the following statements, which include measures to ensure clinical content validity: The abstract submission site is open June 2 - August 2, 2022. ATAC-Seq (for assay for transposase-accessible chromatin with high-throughput sequencing) analysis revealed strong chromatin accessibility at the -globin locus in ZBTB7A/ cells. This line possesses an advantage over lines currently used for globin switching studies because it expresses predominantly adult hemoglobin (HbA: 22), with very low background HbF expression.
The online abstract submission system will provide links so that you can download free browser software. You must disclose the relationship type and the name of the ineligible company for each of the following areas in which you maintain a relationship. ASH will consider such requests on an ad hoc basis.
Abstracts sent via e-mail to ASH will not be accepted. The author(s) agree(s) to materially confine the presentation to information in the abstract, if accepted for presentation.
If none of the abstract authors is an ASH member, the abstract must be sponsored by a current ASH member. It certifies the ASH abstract submitter's understanding of the rules for participation contained in the online abstract submission program and affirms that: A sample abstract is provided for your reference below. Recipients of this award must be a member of HSANZ and reside in Australia or New Zealand. As expected, -globin (HBG1 and HBG2) transcripts, but not those of embryonic -globin (HBE1), were markedly induced in ZBTB7A KO (ZBTB7A/) HUDEP-2 cells. It is assumed that the presenting author will have adequate command of English to present an oral presentation and to respond to questions. Authors must notify ASH if, after the submission deadline, the work submitted for publication is accepted for journal publication and will be published online or in print before the ASH annual meeting. Please include the following items in your letter: Author name (this is the trainee who is the presenting/contact author). Using CRISPR/cas9 gene modification, we knocked out ZBTB7A in HUDEP-2 cells and performed RNA-Seq analysis. Recipients of this award must be members of JSH and reside in Japan. Italic type is acceptable. All relevant conflicts of interest must be disclosed, and data presented fairly and transparently. Release the research/study to news media, or.
Winners must attend the meeting and present their abstract to receive their award, Undergraduate students, medical students, graduate students, resident physicians, and post-doctoral (MD or PhD) fellows who are. Abstracts cannot be changed after the submission deadline and may not be withdrawn after September 16, 2022. All authors approve of submitting this work for presentation and publication; The author(s) transfer(s) all copyright ownership of the named abstract to the American Society of Hematology (except when one or more authors are U.S. Government employees); OR the submitter has gained permission from the copyright holder of the previously published abstract for the abstract to be displayed in the ASH meeting mobile app and online program. This information will be available to reviewers. This option should be selected primarily by authors who would not be willing to present a poster. As the corresponding author, you will receive all future correspondence from ASH. If you indicated at submission that you wish to withdraw your abstract if it is not accepted for either oral or poster presentation, your abstract will be automatically withdrawn, and you will be notified; you do not need to request withdrawal. We encourage non-English-speaking authors to have their abstracts checked for grammar and spelling prior to submission. Disclosed information may include the following areas: You will be required to note whether your presentation will include discussion of off-label use of products. Here, we show that Leukemia/lymphoma Related Factor (LRF), encoded by the ZBTB7A gene, is a novel and potent repressor of HbF production. By submitting a previously published abstract. For previously published abstracts, see Copyright section below. Any technical questions regarding navigation of the submission site itself should be directed to ash@confex.com. Use numerals to indicate numbers, except when beginning sentences. Additional requirements to apply for the Minority Graduate Student Abstract Achievement Award: Completion of all required disclosure information in the online abstract submission system serves as an agreement and is accepted in lieu of a faxed signature.
Use the information for trading in the securities of any issuer or provide it to others who may use it for securities-trading purposes. Send related correspondence and questions regarding abstract submissions or notifications to: ASHabstracts@hematology.org. Failure to submit presentation by November 16th will result in removal of presenting privileges, to be noted by Presentation Not Available in meeting materials. If you have not received an e-mail notification by October 5, 2022, contact, To ensure that you can receive e-mail correspondence from ASH, please. By completing this section of the online abstract submission, you agree that you have read the. The presentation at the annual meeting must reflect the submitted abstract. Abstracts submitted to ASH are embargoed from the time of submission.
Special Greek and mathematical symbols are available in a character map within the submission system. This annual award in partnership with International Paroxysmal Nocturnal Hemoglobinuria (PNH) Interest Group (IPIG) shall be granted to up to two trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious PNH focused abstracts submitted in the fields of Red Cells and Erythropoiesis or Bone Marrow Failure. These choices must be made at the time of submission and cannot be changed after the review committee has reached its decision. The author(s) are aware that the withdrawal deadline for ASH Annual Meeting abstracts is September 16, 2022, and understand that abstracts cannot be withdrawn after September 16.. To register, you must complete and return an Attendee Registration Form, or. If that is not the case, the authors should choose poster as their preference. The content I am responsible for will be free of logos or other corporate identifiers of healthcare industry companies, specifically those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. If none of the abstract authors is an ASH member, the program will ask you to provide the name of the ASH member who is sponsoring the abstract. Our findings reveal a novel molecular mechanism regulating -globin silencing and may open a new window for therapeutic targeting in the treatment of hemoglobinopathies. Upon abstract acceptance for presentation at the annual meeting, the contents and conclusions of the abstract are embargoed from publication.
During submission, submitters must choose the formats in which they would be willing to present/publish their abstract. During online submission, you must indicate whether you prefer to have your abstract withdrawn if it is not accepted as an oral or poster presentations at the ASH annual meeting. (Note the exception for abstracts submitted to other ASH meetings in the Eligibility section above.) The presenting author must be one of the co-authors listed on the submitted abstract. This means that the data in the abstract cannot be published in a journal once submitted for the ASH annual meeting until the meeting is concluded.
Dr. Bigi served as associate professor of Clinical Immunology at the University of Milan from 1985 until his death in 2002 and was one of the first researchers to predict the presence of stem cells in the peripheral blood. 5MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Oxford University, Oxford, United Kingdom All research and studies reported in submitted abstracts that involve human and animal subjects must comply with the guiding principles for experimentalprocedures, Data from the long-term follow-up of previously presented or published clinical trials may be submitted only if significant new information can be shown. The list of award recipients will also be posted on the ASH website by November.
In the event that an abstract is not chosen for oral presentation, it can still be chosen for poster presentation. 4School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, Australia Netscape Navigator 7.7+ is supported, but its use is discouraged, since not all features are available. The64th Annual Meeting of the American Society of Hematology (ASH) will be held Saturday, December 10, through Tuesday, December 13, 2022, in New Orleans, Louisiana. We realize decisions about attendance may not be feasible before the abstract submission deadline, and we will accommodate necessary changes as needed. Please note that submitting an abstract does not register you for the ASH annual meeting. This annual award in partnership with the Japanese Society of Hematology (JSH) shall be granted to up to three trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are. Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by ASH.
Notably, the HbF reactivation occurred without changes in levels of transcripts encoding known HbF repressors, including BCL11A, the principal known switching factor. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committee or review panels, board memberships, and other activities from which remuneration is received, or expected. Authors assign copyright of the abstract to ASH upon submission, unless one of the authors is a U.S. Federal employee (in such case, ASH does not hold copyright). Funnell, PhD4, Chris Fisher, PhD5, Maria Suciu5, Gabriella E. Martyn4, Laura J. Norton4, Ruijia Zhu1, Ryo Kurita, PhD6, Yukio Nakamura, MD, PhD6, Jian Xu, PhD7, Douglas R. Higgs, FRS5, Merlin Crossley, DPhil4, Daniel E. Bauer, MD, PhD3, Stuart H. Orkin, M.D.8, Peter V. Kharchenko, PhD2 and Takahiro Maeda, MD, PhD1 Research funding from ineligible companies should be disclosed by the principal or named investigator even if that individuals institution receives the research grant and manages the funds. If the first author is unable to attend in person, another abstract author able to attend in person may be substituted as the presenter. Purchase orders and checks will not be accepted.
To apply, applicants must first submit an abstract as a trainee to the ASH annual meeting through the online abstract submission system by August 2, 2022. If no financial relationships with ineligible companies exist, this must be stated as well.
Supporting a direct role of LRF at the -globin cluster, we observed several significant enrichment of LRF-ChIP binding signals at adult (HBB), fetal (HBG1) globin loci and the upstream hypersensitivity (HS) sites within the locus control region (LCR). Data from peer-reviewed content is publicly available via major search engines (such as PubMed, Google Scholar, etc.). If an author has more than one abstract accepted, each presentation will be materially confined to the information in the abstract selected for the specific session; The presenting author will be available to present the abstract if selected for the program. HbF levels in LRF KD cells (49-70%) were much greater than those seen in parental or scrambled-shRNA transduced cells. Any references should be noted as citations within the text and not as footnotes at the end of the abstract. Each awardee shall receive a $2,000 grant and complimentary registration to the current years ASH annual meeting.
Minority Graduate Student Abstract Achievement Award applicants will be notified as to whether or not they received an award by late October. Strikingly, HUDEP-2 lines lacking both LRF and BCL11A exhibited almost a complete switch in expression from adult- to fetal-type globin, suggesting that these two factors cumulatively represent the near entirety of -globin repressive activity in adult erythroid cells. More information on requesting such an exception can be found on the. Once the abstract is submitted to ASH, no further changes can be made to the preprint, including the abstract, nor may the preprint be updated if the abstract is accepted for presentation at ASH. If I have been trained or utilized by an ineligible company (commercial interest) or its agent as a speaker (e.g. Electronic submission works optimally with Microsoft Internet Explorer 7+, Mozilla Firefox 3.0+, and Safari or MAC OS 10.4+. Abstracts should be written in clear and concise English, so that reviewers are able to focus solely on the scientific merits of the submission. In addition, this platform will help increase the visibility of ongoing clinical trials; and ultimately facilitate patient recruitment.
Be sure to select from the review category that best describes your abstract. Non-proprietary (generic/scientific) names should be used and should be lowercase. Each abstract author agrees and certifies that they: have read all the rules and agrees to be bound by them, are responsible for submission of the abstract in accordance with the rules, and. There will be no exceptions. Your letter must be typed on your institutions letterhead, signed by the senior investigator, saved in PDF format, and uploaded to the online abstract submission system. ASH requires that abstract presenters of oral or poster presentations attend the meeting and present their abstract and respond to questions in person. 8Department of Pediatric Hematology-Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Conflict-of-Interest Disclosure Policy, Author Responsibility Regarding Financial Relationship Disclosure. In particular, the abstract title, authorship, and scientific content of the presentation at the annual meeting must match the submitted abstract, although updates on results may be added. This annual award in partnership with the Haematology Society of Australia and New Zealand (HSANZ) shall be granted to up to two trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are. If after the September 16 withdrawal deadline, the presenting author of a poster is unable to attend the meeting in person and a co-author cannot be identified to replace the presenter, the author should submit a request to, All abstracts accepted for presentation (plenary, oral, or poster) at the ASH annual meeting are published in a special online-only issue of, Previously published abstracts will not be published in, Abstracts not selected for presentation will also be published online-only on the. Non-members will be able to find all relevant annual meeting information on the ASH website and can access the online registration and hotel reservation program beginning August 10, 2022. Use standard abbreviations. Authors must retain copyright of the abstract so that it may be transferred to the American Society of Hematology if the abstract is accepted, per ASHs copyright policy. Poster presentations will consist of 3-5 minute recordings accompanying a slide deck on the virtual platform. Submissions that are incomplete by the deadline will be rejected. TiPs abstracts are expected to provide investigators with opportunities to discuss planned and ongoing clinical trials; enabling translational researchers, clinical and industry investigators, statisticians, and regulators to become informed about these clinical trials and to allow for early engagement and collaboration, as appropriate. Abstracts noted with a preference for poster presentation will NOT be considered for oral presentation, regardless of score. Any recommendations for patient care must be based on current science, evidence, and clinical reasoning, while giving a fair and balanced view of diagnostic and therapeutic options. Abstracts may not be withdrawn after September 16. The recipient receives a $5,000 grant and a $1,000 allowance for travel and expenses to the ASH annual meeting. Authors select whether they prefer oral or poster presentation. Takeshi Masuda, PhD1, Xin Wang, PhD2, Manami Maeda, M.D., PhD1, Matthew C. Canver, B.S.3, Falak Sher, PhD3, Alister P.W.
For ASH members, Early-Bird Registration will be available July 20, 2022. The site opens on Thursday, June 2, and the abstract submission deadline is Tuesday, August 2, 2022, 11:59 p.m. Pacific time. Obtaining copyright transfer consent from co-authors. An abstract must include primary scientific, clinical, meta-analytic or epidemiologic data. Abstracts describing innovative Trials in Progress (TiP) [i.e., trials that have not reached the primary endpoint] are now eligible for submission and consideration for the ASH annual meeting program. Abstract Achievement Award recipients will be notified if they will receive an award by late October 2022. For the research to be eligible for presentation at the ASH annual meeting, information contained in the abstract, as well as additional data and information to be presented about the research at the annual meeting, may not be made public before the abstract has been published/presented at the ASH annual meeting. Non-text content (. Also, lowercase to when used as an infinitive. speakers bureau) for any commercial interest, the promotional aspects of that presentation will not be included in any way with this activity or publication. Read the Embargo Policy section of the Call for Abstracts for more information. Do not put a period at the end of the title. Your name, degree, institutional affiliation, address, phone number, and e-mail address must be provided. 1Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA Abstract Achievement Award recipients will be notified by email if they will receive an award by late October.
The corresponding author should be the first author (presenter) of the abstract, unless otherwise noted during submission. This annual award is given to an Italian trainee (undergraduate, medical, or graduate student, resident physician, or post-doctoral fellow) based at an Italian institution who is. If necessary, you may include a proprietary name in parentheses directly following the generic name after its first mention in the body of the abstract; the first letter of the name of a proprietary drug should be capitalized. Payment must be made by credit card; Visa, MasterCard, and American Express are accepted. The first author listed for each abstract serves as the presenting author and as the primary contact for all correspondence regarding the abstract, unless otherwise specified under the Contact Information section of the online abstract submission system. To submit an abstract, the following criteria must be met: In contrast to past years, oral abstract and poster presentations will no longer be contained in the ACCME-accredited portion of the annual meeting. We next performed chromatin-immunoprecipitation and sequencing (ChIP-Seq) with an anti-LRF antibody using HSPC-derived proerythroblasts and HUDEP-2 cells. Pre-recorded presentations for both oral and poster presentations are required by November 16th. In addition to the regular eligibility criteria listed above, TiP abstracts must fulfill the following criteria: Recognizing that the results of some top-quality research may not be available by the general abstract submission deadline, the ASH Program Committee offers an option for late-breaking abstracts. The author must provide an explanation (see section below) to show how the abstract contains significant new information. This means that the identical abstract may not be republished or submitted to another meeting. Data are accepted for journal publication before the abstract submission closing date. For such abstracts, copyright remains with the current holder. This annual award is made possible by a grant from the Giuseppe Bigi Association, named for the late Giuseppe Bigi, MD, a well-known Italian scientist. How to be considered for an Abstract Achievement Award: All trainee authors must upload the required letter into the program in order to complete the abstract submission. or unstructured. LRF loss also reactivated human fetal globin expression in vivo in LRF conditional KO mice harboring the human -globin gene cluster as a yeast artificial chromosome transgene (-YAC).
Publication before the meeting may result in the abstract being removed from the meeting.
Pay careful attention to superscripts, type case font sizes, and special characters when copy/pasting abstract text. During this time, ASH members can access the online meeting registration and hotel reservation program before it is open to the general public. If the Embargo Policy is violated, the abstract may be withdrawn by ASH from presentation at the annual meeting and from publication. Registration will open July 20, 2022, for ASH members and August 10, 2022, for non-members.
LRF-deficient adult erythroblasts showed significant induction of Hbb-bh1, but not Hbb-y. Abstracts cannot be submitted and will not be reviewed without proper payment and completion of the Submission Information and Disclosure sections of the online abstract submission program. This annual award in partnership with the Society Italiana di Ematologia (SIE) shall be granted to up to two trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are.
(Please note that declining to have your abstract considered for poster presentation does not improve its chances of being accepted as an oral presentation. An exception may be granted in cases in which the Securities and Exchange Commission (SEC) requires a press release to comply with security laws. ASH abides by rules formulated by the ACCME that require that you disclose any financial relationship you or your spouse/partner have had within the past 24 months with an ineligible company (formerly commercial interest) as defined by the ACCME: Ineligible companies are those whose primary business is producing, marketing, re-selling, or distributing healthcare products used by or on patients. ZBTB7A/ cells exhibited HbF levels greater than 60%, while that of parental cells was less than 3%. During the disclosure submission process, you will also be required to indicate your compliance with the following statements, which include measures to ensure clinical content validity: The abstract submission site is open June 2 - August 2, 2022. ATAC-Seq (for assay for transposase-accessible chromatin with high-throughput sequencing) analysis revealed strong chromatin accessibility at the -globin locus in ZBTB7A/ cells. This line possesses an advantage over lines currently used for globin switching studies because it expresses predominantly adult hemoglobin (HbA: 22), with very low background HbF expression.
The online abstract submission system will provide links so that you can download free browser software. You must disclose the relationship type and the name of the ineligible company for each of the following areas in which you maintain a relationship. ASH will consider such requests on an ad hoc basis.
Abstracts sent via e-mail to ASH will not be accepted. The author(s) agree(s) to materially confine the presentation to information in the abstract, if accepted for presentation.
If none of the abstract authors is an ASH member, the abstract must be sponsored by a current ASH member. It certifies the ASH abstract submitter's understanding of the rules for participation contained in the online abstract submission program and affirms that: A sample abstract is provided for your reference below. Recipients of this award must be a member of HSANZ and reside in Australia or New Zealand. As expected, -globin (HBG1 and HBG2) transcripts, but not those of embryonic -globin (HBE1), were markedly induced in ZBTB7A KO (ZBTB7A/) HUDEP-2 cells. It is assumed that the presenting author will have adequate command of English to present an oral presentation and to respond to questions. Authors must notify ASH if, after the submission deadline, the work submitted for publication is accepted for journal publication and will be published online or in print before the ASH annual meeting. Please include the following items in your letter: Author name (this is the trainee who is the presenting/contact author). Using CRISPR/cas9 gene modification, we knocked out ZBTB7A in HUDEP-2 cells and performed RNA-Seq analysis. Recipients of this award must be members of JSH and reside in Japan. Italic type is acceptable. All relevant conflicts of interest must be disclosed, and data presented fairly and transparently. Release the research/study to news media, or.
Winners must attend the meeting and present their abstract to receive their award, Undergraduate students, medical students, graduate students, resident physicians, and post-doctoral (MD or PhD) fellows who are. Abstracts cannot be changed after the submission deadline and may not be withdrawn after September 16, 2022. All authors approve of submitting this work for presentation and publication; The author(s) transfer(s) all copyright ownership of the named abstract to the American Society of Hematology (except when one or more authors are U.S. Government employees); OR the submitter has gained permission from the copyright holder of the previously published abstract for the abstract to be displayed in the ASH meeting mobile app and online program. This information will be available to reviewers. This option should be selected primarily by authors who would not be willing to present a poster. As the corresponding author, you will receive all future correspondence from ASH. If you indicated at submission that you wish to withdraw your abstract if it is not accepted for either oral or poster presentation, your abstract will be automatically withdrawn, and you will be notified; you do not need to request withdrawal. We encourage non-English-speaking authors to have their abstracts checked for grammar and spelling prior to submission. Disclosed information may include the following areas: You will be required to note whether your presentation will include discussion of off-label use of products. Here, we show that Leukemia/lymphoma Related Factor (LRF), encoded by the ZBTB7A gene, is a novel and potent repressor of HbF production. By submitting a previously published abstract. For previously published abstracts, see Copyright section below. Any technical questions regarding navigation of the submission site itself should be directed to ash@confex.com. Use numerals to indicate numbers, except when beginning sentences. Additional requirements to apply for the Minority Graduate Student Abstract Achievement Award: Completion of all required disclosure information in the online abstract submission system serves as an agreement and is accepted in lieu of a faxed signature.